CardioMEMS HF System Patient Selection & Assessment
Selecting the Right Patient for Remote Pulmonary Artery Pressure Monitoring
The CardioMEMS™ HF System is indicated for patients with:
- NYHA Class II or Class III heart failure; and
- Hospitalized for heart failure in the previous year; and/or
- Elevated natriuretic peptides
The CardioMEMS HF System is contraindicated for patients with:
- An inability to take dual antiplatelet or anticoagulants for one month post-implant
NYHA Classes of Heart Failure
Is your patient indicated for CardioMEMS HF System?
Answer questions to help you determine if your heart failure patient is indicated for the CardioMEMS HF System.
Indication criteria for this quiz is based on the CardioMEMS HF System instructions for use. This quiz is not intended to replace professional expertise or information. Patient selection is always at the discretion of the care team and dependent on each patient's unique condition. Abbott is a medical device manufacturer and cannot provide medical advice.
CardioMEMS HF System Indication Quiz
CardioMEMS HF System: National Coverage Available for Medicare and Medicare Advantage Beneficiaries
The CardioMEMS HF System Coverage with Evidence Development (CED) study is approved by the Centers for Medicare and Medicaid Services (CMS) for the implantable pulmonary artery pressure sensors (IPAPS) National Coverage Determination (NCD). This means all Medicare and Medicare Advantage beneficiaries, including previously denied Medicare Advantage patients, will have access to the CardioMEMS HF System inpatient, outpatient, and at an ASC when policy criteria of NCD is met.
Managing Heart Failure - Who Can Benefit from the CardioMEMS HF System?
Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:1
- Fluid volumes that are hard to know or manage
- Challenging physical assessment
- Is a patient with HFpEF or HFrEF
- Compliant with heart failure medical care
- Would benefit from remote monitoring if they live far from a clinic
Note: The CHAMPION trial specifically excluded patients with American College of Cardiology/ American Heart Association stage D heart failure who needed advanced therapies (i.e., left ventricular assist device, transplant or inotropic support). Even if inotropic support improved heart failure symptoms, a patient would still be defined as stage D, with refractory heart failure.1
References
- Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3
MAT-2006770 v13.0